SCHEMBL10263248

SCHEMBL10263248

Cc1cccc(-c2cocn2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.53
ENPP3 O14638 1/20 0.46
IDO1 P14902 1/20 0.46
METAP2 P50579 1/20 0.46
KMO O15229 2/20 0.44
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
NOTUM Q6P988 1/20 0.42
ATP4A P20648 1/20 0.41
ATP4B P51164 1/20 0.41
KDM1A O60341 1/20 0.41
GRM5 P41594 1/20 0.41
EGFR P00533 1/20 0.41
KDM4E B2RXH2 1/20 0.41
XDH P47989 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14564377 0.79 SCN9A (0.62) SCN9AKMOEGFR
SCHEMBL1354826 0.78 SCN9A (0.53) SCN9AMETAP2RAB9ANPC1HPGD
SCHEMBL17794305 0.78 SCN9A (0.53) SCN9AIDO1METAP2RAB9ANPC1
SCHEMBL4751198 0.78 HSD17B1 (0.58) SCN9AMETAP2ATP4AATP4B
SCHEMBL6202100 0.78 SCN9A (0.56) SCN9AIDO1KMOBCHEACHE
SCHEMBL3635892 0.77 DYRK1A (0.53) SCN9ARAB9ANPC1TSHRSMN1; SMN2
SCHEMBL1251657 0.77 NOTUM (0.50) SCN9ARAB9ANPC1TSHRSMN1; SMN2
SCHEMBL14286107 0.77 SCN9A (0.52) SCN9AIDO1KMOACHENOTUM
SCHEMBL16159336 0.76 SCN9A (0.55) SCN9AENPP3SMN1; SMN2EGFR
SCHEMBL9288053 0.76 ENPP3 (0.47) SCN9AENPP3METAP2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9598432-B2 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents RIGEL PHARMACEUTICALS, INC. (US) 2017-03-21 US disclosed
US-20150011002-A1 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents RIGEL PHARMACEUTICALS, INC. (US) 2015-01-08 US disclosed
US-8809341-B2 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents RIGEL PHARMACEUTICALS, INC. (US) 2014-08-19 US disclosed
WO-2012085852-A1 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES ACTELION PHARMACEUTICALS LTD (CH) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150011002-A1 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents MKI67, TYMP, PCNA SCN9A 4826/4885ENPP3 151/4885IDO1 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.